Analysts Lift Vir Biotechnology Price Target to $25, Some Forecast $35
Analysts raised the consensus price target for Vir Biotechnology from $19.25 to $25.00, with Needham’s Joseph Stringer setting a $35 target. Strategic partnerships with GlaxoSmithKline and the Bill & Melinda Gates Foundation and the success of Sotrovimab for COVID-19 have boosted R&D capabilities and investor sentiment.
1. Consensus Price Target Rises
Analysts increased the consensus price target for Vir Biotechnology from $19.25 to $25.00 over the past year, reflecting growing confidence in the company’s pipeline. Needham analyst Joseph Stringer pushed the high-water mark further with a $35 target, signaling optimism about future growth drivers.
2. Partnerships Enhance R&D Capabilities
Vir Biotechnology has strengthened its research and development through strategic collaborations with GlaxoSmithKline and the Bill & Melinda Gates Foundation. These partnerships provide funding, technical expertise, and shared trial networks aimed at accelerating the development of monoclonal antibodies and other infectious-disease therapies.
3. Sotrovimab Success Boosts Sentiment
The company’s Sotrovimab monoclonal antibody for COVID-19 treatment has demonstrated clinical effectiveness, driving positive market sentiment. Strong real-world performance data for Sotrovimab underpin the upward analyst revisions and bolster confidence in Vir’s commercial potential.
4. Analyst Engagement in Q3 Earnings Call
During the Q3 2025 earnings call, Vir’s management discussed financial performance, pipeline progress, and commercialization plans. Active participation from analysts representing top financial institutions highlighted sustained interest in the company’s strategic direction and long-term outlook.